Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes

British Journal of Haematology

Volumn 122, Issue 2, 2003, Pages 269-271

  Musto, Pellegrino ^a   Falcone, Antonietta ^a   Sanpaolo, Grazia ^a   Bodenizza, Carlo ^a   La Sala, Antonio ^a   Perla, Gianni ^a   Carella, Angelo Michele ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Anaemia; Darboepoetin; Erythropoietin; Myelodysplastic syndromes; Transfusion

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; BLOOD TRANSFUSION; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 0038486973     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04435.x     Document Type: Article

References (12)

1. Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., Visani, G. & Tura, S. (2002) Evidence- and consensus-based practice guidelines for the therapy of myelodysplastic syndromes: a statement from the Italian Society of Hematology. Haematologica, 87, 1286-1306.
2. Aloe-Spiriti, M.A., for The Italian Fatigue/QoL MDS Cooperative Group (2002) Effects of 40.000 IU bi-weekly induction dose of Epoetin alpha followed by 40.000 IU once weekly in low risk myelodysplastic syndrome patients. Blood, 100, 790a.
3. Cazzola, M., Coiffier, B., Kloczko, J. & Spika, I. (2002) Once weekly Neorecormon (epoetin beta) for the treatment of anemia associated with lymphoproliferative malignancies: results of the NOW (Neorecormon once-weekly) study. The Hematology Journal, 3, 64.
4. Cheung, W., Minton, N. & Gunawardena, K. (2001) Pharmacokinetics and pharmacodynamics of epoetin alpha once weekly and three times weekly. European Journal of Clinical Pharmacology, 57, 411-418.
5. Gabrilove, J.L., Cleeland, C.S., Livingstone, R.B., Sarokhan, B., Winer, E. & Einhorn, L.H. (2001) Clinical evaluation of once-weekly dosing of epoetin alpha in chemotherapy patients: improvement in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19, 2875-2882.
6. Hellstrom-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology, 89, 67-71.
7. Italian Cooperative Study Group for r-Hu-Epo in Myelodysplastic Syndromes (1998) A randomized, double-blind, placebo-controlled study with subcutaneous human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology, 103, 1070-1074.
8. Rigokin, G.M., Della Porta, M., Bigoni, R., Cavazzini, F., Ciccone, M., Bardi, A., Cuneo, A. & Castoldi, G.L. (2002) r-HuEPO administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald - Giemsa-stained bone marrow samples. British Journal of Haematology, 119, 652-659.
9. Rizzo, J.D., Lichtin, A.E., Woolf, S.H., Seidenfeld, J., Bennett, C.L., Cella, D., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Lee, S.J., Miller, C.B., Rarick, M.U., Regan, D.H., Browman, J.P. & Gordon, M.S. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 100, 2303-2320.
10. Smith, R. (2002) Applications of darboepoietin alpha, a novel erythropoiesis-stimulating protein, in oncology. Current Opinion in Hematology, 9, 228-233.
11. Terpos, E., Mugiou, A., Kouraklis, A., Chatzivasili, A., Michalis, E., Giannakoulas, N., Mantoudaki, E., Lazaridou, A., Bakaloudi, V., Protopappa, M., Liapi, D., Grouzi, E., Parharidou, A., Symeonidis, A., Kokkini, G., Laoutaris, P., Vaipoulos, G., Anagnostopoulos, N.I., Christakis, J., Meletis, J., Bourantas, K.L., Zoumbos, N.C., Yataganas, X. & Viniou, N.A. (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodys-plastic syndromes: a phase II trial in 281 patients. British Journal of Haematology, 118, 174-180.
12. Yount, S., Lai, J.S. & Cella, D. (2002) Methods and progress in assessing quality of life effects of supportive care with erythropotetin therapy. Current Opinion in Hematology, 9, 234-240.